Novo Nordisk (NYSE: NVO) just made a partnership play worth $600 million with a small biotech called NanoVation that might just change the stock's trajectory for many years to come. On Sept.

Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic ...

BusinessWire India Mumbai Maharashtra Hyderabad Telangana [India] October 30 PopVax an Indian full-stack biotechnology ...

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

Justin Welby, the leader of 85 million Anglicans worldwide, announced his resignation days after a report found he had taken insufficient action over claims of abuse. By Stephen Castle and Mark ...

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...

Nov. 11, 2024 — Why is the expansion of our Universe accelerating? Twenty-five years after its discovery, this phenomenon remains one of the greatest scientific mysteries. Solving it involves ...

Nov. 6, 2024 — Researchers have developed AI-driven mobile robots that can carry out chemical synthesis research with extraordinary efficiency. Researchers show how mobile robots that use AI ...

The new Veterans Community will support veteran workforce development and transition to civilian life for former members of any branch of the U.S. military and their spouses.

MarketBeat Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications NanoVation Therapeutics partners with Novo Nordisk to develop genetic medicines ...

Justin Welby, the leader of 85 million Anglicans worldwide, announced his resignation days after a report found he had taken insufficient action over claims of abuse. By Stephen Castle and Mark ...